Wockhardt Bio AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Subsidiary
- Established
- 2005-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.wockhardtbio.com
Clinical Trials
42
Active:11
Completed:17
Trial Phases
3 Phases
Phase 1:21
Phase 3:7
Not Applicable:5
Drug Approvals
2
NMPA:2
Drug Approvals
Piperacillin Sodium and Tazobactam Sodium for Injection
- Product Name
- 注射用哌拉西林钠他唑巴坦钠
- Approval Number
- 国药准字HJ20233136
- Approval Date
- Mar 21, 2023
NMPA
Piperacillin Sodium and Tazobactam Sodium for Injection
- Product Name
- 注射用哌拉西林钠他唑巴坦钠
- Approval Number
- 国药准字HJ20233137
- Approval Date
- Mar 21, 2023
NMPA
Clinical Trials
Distribution across different clinical trial phases (33 trials with phase data)• Click on a phase to view related trials
Phase 1
21 (63.6%)Phase 3
7 (21.2%)Not Applicable
5 (15.2%)Phase 3 Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Phase 3
Not yet recruiting
- Conditions
- 10 Acute tubulo-interstitial nephritisN390 Urinary tract infection, site not specifiedAcute tubulo-interstitial nephritisUrinary tract infection, site not specifiedN390
News
No news found